{"nctId":"NCT00006011","briefTitle":"Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer","startDateStruct":{"date":"2000-07"},"conditions":["Endometrial Adenocarcinoma","Endometrial Adenosquamous Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation","Endometrial Serous Adenocarcinoma","Stage III Uterine Corpus Cancer"],"count":659,"armGroups":[{"label":"Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)","type":"EXPERIMENTAL","interventionNames":["Drug: Doxorubicin Hydrochloride","Drug: Cisplatin","Biological: Filgrastim","Biological: Pegfilgrastim"]},{"label":"Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)","type":"EXPERIMENTAL","interventionNames":["Drug: Doxorubicin Hydrochloride","Drug: Cisplatin","Biological: Filgrastim","Biological: Pegfilgrastim","Drug: Paclitaxel"]}],"interventions":[{"name":"Doxorubicin Hydrochloride","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Filgrastim","otherNames":["G-CSF","Nivestim","r-metHuG-CSF"]},{"name":"Pegfilgrastim","otherNames":["Filgrastim SD-01","GCSF-SD01","Neulasta"]},{"name":"Paclitaxel","otherNames":["Anzatax","TAX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed advanced endometrial carcinoma with any histology, including:\n\n  * Clear cell and serous papillary carcinoma\n* Surgical stage III disease, including:\n\n  * Positive adnexa\n  * Tumor invading the serosa\n  * Positive pelvic and/or paraaortic nodes\n  * Involvement of bowel mucosa\n  * Intraabdominal metastases\n  * Positive pelvic washings\n  * Vaginal involvement within the radiation port\n* Must have had prior surgery, including hysterectomy and bilateral salpingo-oophorectomy\n\n  * Tumor maximally debulked to a maximum residual diameter of no greater than 2 cm\n  * Paraaortic lymph node sampling allowed\n\n    * If positive, must have negative chest CT scan\n* No recurrent disease\n* No parenchymal liver metastases\n* No disease outside the abdomen\n* Performance status - GOG 0-2\n* At least 3 months\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin no greater than 1.5 times normal\n* SGOT/SGPT no greater than 3 times normal\n* Alkaline phosphatase no greater than 3 times normal\n* Creatinine no greater than 1.6 mg/dL\n* LVEF at least 50% within 6 months of study entry\n* No other prior or concurrent malignancy within the past 5 years except adequately treated nonmelanoma skin cancer\n* No serious comorbid illness that would preclude study participation\n* No prior chemotherapy\n* See Disease Characteristics\n* No prior pelvic or abdominal radiotherapy\n* No prior radiotherapy for prior malignancy\n* See Disease Characteristics","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.","description":"Recurrence is defined as discovery of disease not previously present by clinical, radiographic, and/or laboratory means or as a 50% or greater increase in the product of two perpendicular diameters from any documented lesion.\n\nRecurrence-free survival is defined as time in months the patient is alive, recurrence-free starting from the date of randomization.\n\nIntention to treat among eligible participants who receive random treatment allocation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"175","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":261},"commonTop":["Leukopenia","Neutropenia","Alopecia","Anemia","Constitutional"]}}}